<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68624">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212457</url>
  </required_header>
  <id_info>
    <org_study_id>V102_15</org_study_id>
    <nct_id>NCT02212457</nct_id>
  </id_info>
  <brief_title>Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents</brief_title>
  <official_title>A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to Novartis Meningococcal Group B Vaccine, in Healthy Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The main purposes for conducting the study are firstly to assess immunological
      non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to
      healthy adolescents 10 to 18 years of age, to those of the licensed rMenB+OMV vaccine
      (Bexsero™) in terms of hSBA GMTs at one month after the second vaccination, secondly to give
      the flexibility for the national vaccination program by showing the safety and
      immunogenicity of MenABCWY administrated according to four different vaccination schedules
      and additionally to evaluate a potential benefit of the 3-dose vaccination series.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hSBA GMTs against each of N. meningitidis serogroup B test strains (B_0_2 and ABCWY_0_2 groups only)</measure>
    <time_frame>1 month after the last meningococcal vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs against each of N. meningitidis serogroups A, C, W and Y and serogroup B test strains.</measure>
    <time_frame>1 month after the last meningococcal vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with hSBA titers ≥ LLQ, ≥ 5, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥ 128 against each of N. meningitidis serogroups A, C, W and Y and serogroup B test strains</measure>
    <time_frame>Month 0 (baseline), Month 2, Month 3, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with hSBA titers ≥LLQ against all four N. meningitidis serogroups (A, C, W and Y) and against all four serogroup B test strains.</measure>
    <time_frame>Month 0 (baseline), Month 2, Month 3, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with hSBA titers ≥LLQ against N. meningitidis serogroups C and Y, and three serogroup B test strains (fHbp, NadA and NHBA).</measure>
    <time_frame>Month 0 (baseline), Month 2, Month 3, Month 7, and Month 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with two-, three-, and four-fold rise in hSBA titers against the N. meningitidis serogroups A, C, W and Y and serogroup B test strains.</measure>
    <time_frame>Month 2, Month 3, Month 7, and Month 13 with respect to baseline (Month 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (AUC Month 0 - Month 13) for % of subjects with hSBA titers ≥LLQ for all serogroups (A,C,W&amp;Y) &amp; for all serogroup B test strains &amp; for subjects with hSBA≥LLQ for serogroups C and Y, &amp; fHbp, NadA and NHBA test strains only.</measure>
    <time_frame>from Month 0 to Month 13</time_frame>
    <description>serogroup B test strains: fHbp, NadA, NHBA and PorA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs against additional serogroup B strains (fHbp and NadA).</measure>
    <time_frame>1 month after the second meningococcal vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of subjects with hSBA≥1:5 against additional serogroup B strains (fHbp and NadA).</measure>
    <time_frame>1 month after the second meningococcal vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any AEs reported within 30 minutes after each vaccination</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited local and systemic AEs reported from Day 1 to Day 7 after each and any vaccination</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other indicators of reactogenicity within 7 days after each and any vaccination</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited AEs reported from Day 1 to Day 30 after each and any vaccination</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs leading to premature withdrawal from the study</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAEs reported during the entire study period</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1063</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Group ABCWY_0_1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 150 subjects receiving MenABCWY vaccine at Visit Month 0 and Visit Month 1, Hepatitis A vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ABCWY_0_6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 150 subjects receiving MenABCWY vaccine at Visit Month 0 and Visit Month 6, Hepatitis A vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ABCWY_0_11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 150 subjects receiving MenABCWY vaccine at Visit Month 1 and Visit Month 12, Hepatitis A vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ABCWY_0_2_6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 150 subjects receiving MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6, Hepatitis A vaccine at Visit Month 1 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ABCWY_0_2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 225 subjects receiving MenABCWY vaccine at Visit Month 0 and Visit Month 2, Hepatitis A vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B_0_2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>approximately 225 subjects receiving rMenB+OMV vaccine at Visit Month 0 and Visit Month 2, Hepatitis A vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV</intervention_name>
    <arm_group_label>Group B_0_2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group ABCWY_0_1</arm_group_label>
    <arm_group_label>Group ABCWY_0_6</arm_group_label>
    <arm_group_label>Group ABCWY_0_11</arm_group_label>
    <arm_group_label>Group ABCWY_0_2</arm_group_label>
    <arm_group_label>Group B_0_2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix Monodose Vaccine</intervention_name>
    <arm_group_label>Group ABCWY_0_1</arm_group_label>
    <arm_group_label>Group ABCWY_0_6</arm_group_label>
    <arm_group_label>Group ABCWY_0_11</arm_group_label>
    <arm_group_label>Group ABCWY_0_2_6</arm_group_label>
    <arm_group_label>Group ABCWY_0_2</arm_group_label>
    <arm_group_label>Group B_0_2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABCWY</intervention_name>
    <arm_group_label>Group ABCWY_0_1</arm_group_label>
    <arm_group_label>Group ABCWY_0_6</arm_group_label>
    <arm_group_label>Group ABCWY_0_11</arm_group_label>
    <arm_group_label>Group ABCWY_0_2_6</arm_group_label>
    <arm_group_label>Group ABCWY_0_2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adolecents from 10-18 yearsof age, generally in good health, and available for all
             study visits, and who/whose legally acceptable representative has given written
             informed consent at the time of enrollment.

          2. Individuals of who the investigator believes can and will comply with the
             requirements of the protocol (e.g. use of an eDiary, return for follow-up visits,
             available for phone contacts).

          3. Female subjects of childbearing potential must have a negative urine preganancy test.

        Exclusion Criteria:

          1. Serious, acute, or chronic illness. Previous or suspected disease caused by N.
             meningitidis. Previous immunization with any menincococcal or Hepatitis A vaccines.

          2. Exposure to individuals with clicically proven meningococcal disease or clinical
             bacterial meningitis without further microbiologic characteriszation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>308, Novartis Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>327, Novartis Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304, Novartis Investigational SIte</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>335, Novartis Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>326, Novartis Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>324, Novartis Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Michigan</state>
        <zip>49120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>334, Novartis Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302, Novartis Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>328, Novartis Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>307, Novartis Investigational Site</name>
      <address>
        <city>Binghamton,</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>329, Novartis Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>313, Novartis Investiogational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>323, Novartis Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>310, Novartis Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>337, Novartis Investigational Site</name>
      <address>
        <city>Mt Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>325, Novartis Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101, Novartis Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103, Novartis Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>102, Novartis Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104, Novartis Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105, Novartis Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>106, Novartis Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107, Novartis Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108, Novartis Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>109, Novartis Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>110, Novartis Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>111, Novartis Investigational Site</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>206, Novartis Investigational Site</name>
      <address>
        <city>Dębica</city>
        <zip>39200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>208,Novartis Investigational Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>209, Novartis Investigational Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201, Novartis Investigatonal Site</name>
      <address>
        <city>Lodz</city>
        <zip>91347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>204, Novartis Investigational Site</name>
      <address>
        <city>Osielsko</city>
        <zip>86031</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>203, Novartis Investigational Site</name>
      <address>
        <city>Siemianowice Śląskie</city>
        <zip>41103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205, Novartis Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202, Novartis Investigation Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 8, 2016</lastchanged_date>
  <firstreceived_date>August 6, 2014</firstreceived_date>
  <firstreceived_results_disposition_date>May 29, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
